Pfizer (PFE) offered up some more details on its weight loss drug pipeline on Tuesday during a call with investors after it ...

吃饭的时候，你喜欢一口菜配一口饭，还是先吃点菜再吃主食？西餐是先吃沙拉再吃主菜，还是一上来就把餐前面包吃光？研究发现，完全一样的食物，用不同的顺序吃下去，餐后血糖升高幅度可能翻倍。吃饭时调整食物的进食顺序，对健康人来说，可以明显减小血糖水平波动，也许 ...

代谢相关脂肪性肝病（MAFLD）及其严重类型代谢相关脂肪性肝炎（MASH）在全球范围内呈现出逐年攀升的发病趋势，已成为威胁人类肝脏健康的重大挑战。在2024年中国国际进口博览会医疗器械及医药保健板块，MASH及其相关纤维化的新药研发动态引起了广泛关注 ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

We aimed to investigate whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the diabetic state.

礼来公司(NYSE: LLY)在2024年10月30日的第三季度业绩电话会议上展示了强劲的财务表现,在其糖尿病和癌症药物Mounjaro和Zepbound的推动下,收入增长显著,达42%。公司的战略投资和管线开发为持续增长奠定了基础,这反映在更新后的2024年收入指引和第四季度预期增长中。 要点 礼来公司报告2024年第三季度收入增长42%(不包括剥离的奥氮平产品组合)。 Mounjaro和Zep ...

"The GLP1s are relatively new and are being rolled-out as scale. We have no idea what damage 20 years of drug-induced ...

A previous study with this incretin triagonist delivered transenterically demonstrated pharmacodynamic effects comparable to subcutaneous injection. Rani also previously completed a study ...

马里兰州盖瑟斯堡 - 临床阶段生物制药公司Altimmune, Inc. (NASDAQ:ALT)宣布，已与美国食品和药物管理局(FDA)就其肥胖治疗候选药物pemvidutide的三期注册计划设计达成一致。这一决定是在全面审查了包括六项先前临床试验结果在内的临床前和临床数据后做出的。 三期计划预计将在四项试验中招募约5,000名受试者，旨在评估pemvidutide 1.2毫克、1.8毫克和2.

LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...